Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Dose-Banding of Intravenous Piperacillin-Tazobactam in Pediatric Surgical Inpatients

Dosing errors are the most commonly reported medication error in children. Dosing is often prescribed per weight or based on body area.

Research

Paediatrician beliefs and practices around influenza vaccination

We aimed to determine Australian paediatricians' beliefs and practices around the influenza vaccination of children.

Research

The AREST CF experience in biobanking - More than just tissues, tubes and time.

Research to further improve outcomes for people with CF is dependent upon well characterised, archived and accessible clinical specimens.

Research

EEG power at 3 months in infants at high familial risk for autism

Reduced frontal power at 3 months may indicate increased risk for reduced expressive language skills at 12 months.

Research

High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations: A prospective cohort study.

High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations.

Research

Age at surgery and outcomes of an undescended testis

We investigated the prevalence of UDT and examined rates of surgery and age at surgery in an Australian population.

Research

Epigenetic modifications: Mechanisms of disease and biomarkers of food allergy

The rise in IgE-mediated food allergy in recent times is the likely result of gene-environment interactions mediated via epigenetic pathways.

Research

Predictors of Outcome in Pediatric Osteomyelitis: Five Years Experience in a Single Tertiary Center

A risk prediction model allows early identification of children at greatest risk of developing complicated osteomyelitis

Research

Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.